INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Latest Information Update: 25 Jun 2025
At a glance
- Drugs Insulin (Primary) ; Insulin detemir (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INHALE-1
- Sponsors MannKind Corporation
Most Recent Events
- 22 Jun 2025 According to The American Diabetes Association media release, results from the INHALE-1 study were presented today as a symposium at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago.
- 22 Jun 2025 Results presented in the American Diabetes Association Media Release.
- 09 Jun 2025 According to a MannKind Corporation media release, Dr. Haller is the Chair for Phase 3 INHALE-1 study.